

Organized by



**Fondazione
Melanoma**

In collaboration with



Society for Immunotherapy of Cancer

Under the auspices of



MELANOMA ²⁰²⁵ BRIDGE

Naples (Italy)

December 4th-6th, 2025

Royal Continental Hotel

Via Partenope 38-42


www.melanomabridge.org - info@melanomabridge.org

General Information

Congress venue

Royal Continental Hotel

Via Partenope 38-42, 80121 Naples



Registration

Registration fee: €880,00 + VAT 22%

Reduced registration fee for AIOM Members: €600,00 + VAT 22%

For information, registration and payments, please contact:

registration@melanomabridge.org

Confirmation of registration will be sent by the Organizing Secretariat.

Only registered participants will be admitted to the event.

» The registration fee includes:

- Participation in scientific sessions
- Congress kit (badge, notepad, pen)
- Coffee breaks and lunches

Official language

The official language is English.

Scientific Rational

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immune-evasion strategies has resulted in different approaches to target and harness the immune response.

Approval of new immune and target therapies has further improved outcomes for patients with advanced melanoma.

The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

This year latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the session dedicated to system biology on immunotherapy, immunogenicity and gene expression profiling and focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.

Then, the "Great Debate" sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view.

Scientific Program

DAY 1 Thursday, Dec 4th

OPENING CEREMONY**

Chairpersons: **Paolo A. Ascierto, Francesco Marincola**

6.00 pm Update in Neoadjuvant research
Christian Blank

6.20 pm Update in T Cell-based therapy
Chrystal M. Paulos

6.40 pm Uveal Melanoma: Further Progress on Targets, Therapies, Trials
...and Leadership
Kevin O'Neill, Marlana Orloff

7.10 pm Melanoma Funding in Crisis - How MRA is Expanding and Funding Research
Initiatives in Cutaneous and Rare Melanomas
Marc Hurlbert

7.25 pm Patient Advocacy reloaded
Samantha Guild, Claudia Piazza Cidonio

**Speakers to be confirmed*

*** Not included in the CME accredited program*

Scientific Program

DAY 2 Friday, Dec 5th

8.20 am **Critical Hurdles in Melanoma Management - Session 1**
Paolo A. Ascierto, Allison Betof Warner, Hussein Tawbi

9.20 am Introduction and objectives
Paolo A. Ascierto

SESSION 1 - MORE TRANSLATIONAL RESEARCH IN MELANOMA

Chairpersons: **Magdalena Thurin***, **Lisa Villabona**

9.30 am Advances in melanoma screening
Sapna Patel, Magdalena Thurin*, **Lisa Villabona**

9.45 am Deploying Artificial Intelligence to Predict Response to treatment
Iman Osman

10.00 am Next generation immunotherapy approach
Jason J. Luke

10.15 am Multiomics tumor profiling for guiding treatment of melanoma after standard of care
Reinhard Dummer

10.30 am TMB
Marc S. Ernstoff

10.45 am Discussion

11.15 am **Coffee Break****

11.30 am **SYMPOSIUM**
The key role of treatment in the Early Stages of Melanoma
Paolo A. Ascierto, Georgina V. Long

GREAT DEBATE

Chairpersons: **Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov, Alessandro Testori**

12.20 pm Triple combination: 1L or 2L
James Smithy vs Hussein Tawbi

12.45 pm Second adjuvant: Immuno VS Target
Omid Hamid vs Reinhard Dummer

1.10 pm **Lunch****

**Speakers to be confirmed*

***Not included in the CME accredited program*

Scientific Program

DAY 2 Friday, Dec 5th

SESSION 2 - PREDICTING AND MANAGING IMMUNE-RELATED ADVERSE EVENTS

Chairperson: **Ryan Sullivan**

- 2.00 pm Prediction
Tomas Kirchhoff
- 2.15 pm Mechanism
Alexandra-Chloe Villani
- 2.30 pm Management
Douglas B. Johnson
- 2.45 pm What about Neurotoxicity
Iman Osman
- 3.00 pm Discussion

3.20 pm **SYMPOSIUM**
The new era of Target Therapy in Metastatic Melanoma
Paolo A. Ascierto, Reinhard Dummer

4.10 pm **SYMPOSIUM - Evolving TCR Therapy in Metastatic Uveal Melanoma**
Development of TCR therapy and how this changed the landscape of metastatic uveal melanoma (mUM) treatment
Christoffer Gebhardt
TCR therapeutics in the clinic (Italian real life): lessons learnt from metastatic uveal melanoma (mUM),
Ester Simeone

GREAT DEBATE

Chairpersons: **Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov**

- 5.00 pm The challenge of neoadjuvant in early disease: possible VS impossible
Georgina V. Long vs Christian Blank
- 5.25 pm Next generation CAR-T VS TILs
Hussein Tawbi vs Allison Betof Warner
- 5.50 pm Leptomeningeal disease: Intrathecal treatment VS Proton Craniospinal RT
Isabella C. Glitza Oliva vs Michael A. Postow

**Speakers to be confirmed*

*** Not included in the CME accredited program*

Scientific Program

DAY 3 Saturday, Dec 6th

SESSION 3 - EMERGENT STRATEGIES

Chairpersons: **Mario Mandalà, Giuseppe Palmieri**

- 9.00 am Managing downside to improve upside: targeting toxicity for efficacy gains
Janice Mehnert
- 9.15 am NRAS Mutant Melanoma: preclinical front
Poulikos Poulikakos
- 9.30 am NRAS Mutant Melanoma: clinical front
Jeffrey Sosman
- 9.45 am Escalation/de-escalation trials involving combination immunotherapy
Michael A. Postow
- 10.00 am Discussion
- 10.20 am SLNB is dead, Neoadjuvant is salvage approach
Alexander M. M. Eggermont
- 10.35 am Oncolytic Therapy
Michael K. Wong
- 10.50 am Biomarkers on clinical trials
Christoffer Gebhardt
- 11.05 am Beta-Blockers targeting stress
Benjamin Switzer
- 11.20 am The evolution of the immune microenvironment during oncogenesis in precancerous lesions
Jerome Galon
- 11.35 am Holistic patient embeddings to predict therapy, survival and exceptional responders
Carlo Bifulco
- 11.50 am Discussion
- 12.15 pm **Critical Hurdles in Melanoma Management - Session 2**
Paolo A. Ascierto, Allison Betof Warner, Hussein Tawbi
- 1.15 pm **Lunch****

**Speakers to be confirmed*

*** Not included in the CME accredited program*

Scientific Program

DAY 3 Saturday, Dec 6th

GREAT DEBATE

Chairpersons: **Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov**

- 2.00 pm H&E conventional VS AI signature
Janis M. Taube vs Olivier Michielin
- 2.25 pm Gene expression profiling in the primary lesion: yes or no
Alexander M. M. Eggermont vs Jeffrey E. Gershenwald*
- 2.50 pm EX VIVO vs IN VIVO transfer
Magdi Elsallab vs Kevin Friedman
- 3.15 pm **Critical Hurdles in Melanoma Management - Session 3**
Paolo A. Ascierto, Allison Betof Warner, Hussein Tawbi
- 4.30 pm Conclusion
Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov

**Speakers to be confirmed*

*** Not included in the CME accredited program*

Presidency



Paolo A. Ascierto

Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione "G. Pascale", Naples, Italy



Corrado Caracò

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy



Iman Osman

Rudolf Baer Professor of Dermatology Professor, Departments of Medicine (Oncology) and Urology Director, NYU Melanoma SPORE Associate Dean for Clinical Research Strategy NYU Grossman School of Medicine, New York, NY, US



Igor Puzanov

Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Scientific Board

Sanjiv S. Agarwala

Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

Paolo A. Ascierto

Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione "G. Pascale", Naples, Italy

Carlo Bifulco

Chief Medical Officer, Providence Genomics, Director of Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Christian Blank

Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Scientific Board

Elizabeth M. Burton

Executive Director, Translational Research Initiative Development, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

Lisa H. Butterfield

Ph.D., Distinguished Scientist Discovery Oncology, Merck Research Labs, South San Francisco, CA, US

Corrado Caracò

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy

Mary Dean

Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

Sandra Demaria

Professor of Radiation Oncology, Professor of Pathology and Laboratory Medicine Weill Cornell Medicine, New York, NY, US

Reinhard Dummer

Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

Alexander M.M. Eggermont

Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical&Translational Immunotherapy, Utrecht University, Utrecht, Netherlands

Leisha A. Emens

Senior Vice President Translational Research, Ankyra Therapeutics, Incorporated, Boston, MA, US; Past President of Society for Immunotherapy of Cancer (SITC)

Bernard A. Fox

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Center Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Jerome Galon

Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

Jeffrey E. Gershenwald

Dr. John M. Skibber Endowed Professor of Surgery, Department of Surgical Oncology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Distinguished Senior Lecturer, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA

James L. Gulley

Co-Director of the Center for Immuno-Oncology, Center for Cancer Research (CCR), the National Cancer Institute (NCI), Bethesda, MD, US; President of Society for Immunotherapy of Cancer (SITC)

Omid Hamid

Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

Scientific Board

Samir N. Khleif

Director of Center for Immunology and Immunotherapy, Director of The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, US

Giuseppe Masucci

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

Olivier Michielin

Full Professor, Chair of Oncology Department and Precision Oncology Service, Geneva University Hospital, Geneva; Co-Director of the Swiss Cancer Center Léman, Agora - Lausanne, Switzerland

Iman Osman

Rudolf Baer Professor of Dermatology Professor, Departments of Medicine (Oncology) and Urology Director, NYU Melanoma SPORE Associate Dean for Clinical Research Strategy NYU Grossman School of Medicine, New York, NY, US

Giuseppe Palmieri

Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

Michael A. Postow

Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

Igor Puzanov

Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Dirk Schadendorf

Director of the Department of Dermatology, University Hospital Essen, Essen, Germany

Magdalena Thurin

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

Tara Withington

Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

CONTINUING MEDICAL EDUCATION

CME Credits

CME Code: 596-464852 Ed. 1

The course has been accredited with 4,5 CME credits.

To obtain CME credits, participants must attend at least 90% of the total course duration and complete the event evaluation.

National Objective:

Technical and professional content (knowledge and skills) specific to each profession, specialization, and ultra specialized activity, including rare diseases and gender medicine.

Target Audience:

This course is intended at 201 participants among the following professions:

- Pharmacists
- Biologists
- Medical Doctors specializing in:
Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Gastroenterology, Ophthalmology, Respiratory diseases, Internal Medicine, Nephrology, Neurology, Oncology, Radiotherapy, General Surgery, Plastic and Reconstructive Surgery, Gynecology and Obstetrics, Urology, Pathological Anatomy, Clinical Pharmacology and Toxicology, Medical Genetics Laboratory, Nuclear Medicine, Clinical Pathology (Chemical-Clinical Laboratory and Microbiology), Radio diagnostics, Hygiene, Epidemiology, and Public Health, General Medicine (General Practitioners), Nutrition Science and Dietetics, Palliative Care
- Pediatric Nurses
- Nurses

CME Provider

OPT S.p.a.

Via Mauro Macchi 38, 20124 Milano

www.optsalute.it



Organizing Secretariat

Vivenko Srl Società Benefit

Via De Amicis 42, 20123 Milan, Italy

www.vivenko.net

info@melanomabridge.org

